ASH 2016 Highlights

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

Obinutuzumab Prolongs Survival in Follicular Lymphoma

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

By Wayne Kuznar

ASH 2016 Highlights

February 2017, Vol 7, No 2

Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma

By Wayne Kuznar

ASH 2016 Highlights, Multiple Myeloma, Hematologic Malignancies

February 2017, Vol 7, No 2

Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

ASH 2016 Highlights

February 2017, Vol 7, No 2